18:08 EST Janux Therapeutics (JANX) down 46% at $18.50 after JANX007 Phase 1 data in mCRPC
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Janux Therapeutics reports ‘positive’ updated interim data for JANX007
- Promising Potential of Janux Therapeutics: Buy Rating on Strong Clinical and Growth Prospects
- Janux Therapeutics initiated with a Peer Perform at Wolfe Research
- Positive Outlook on Janux Therapeutics Inc. Driven by Promising Prostate Cancer Developments and Strong Financial Position
- Janux Therapeutics price target raised to $46 from $45 at Stifel